What Granules India Bulls Got Right

If you only glanced at Granules India through its capacity expansion plans, regulatory overhang, and debate over peptide CDMO returns, the eventual payoff might come as a surprise. Holding Granules India over the past year would have returned 44.5%, including dividends. Revenue and profit on record for Q2 2027 were higher than Q2 2026, yet that is just one snapshot. If you had been deciding back in November 2025, which risk would have mattered more to you: growth potential or balance sheet strain?

Granules India has already moved. See which of 224 high quality undervalued stocks still trade below our estimates.

The Two Stories Investors Had To Weigh On Granules India

The shares cost ₹552 at the start of the period, so any view on Granules India needed a clear story about where the business might head next.

The bullish narrative pointed to a fair value of ₹700, a price implied by assumptions that expanding API and peptide capacity, plus an aging global population, could support 17.6% revenue growth and margins reaching 13.0%.

The bearish view argued for a fair value of ₹480, based on concerns that peptide CDMO overcapacity, heavier debt and long-gestation projects could keep the future P/E closer to 18.4x.

What The Results Changed For Granules India

Granules India reported Q2 2027 revenue of ₹15,706.59m and net income of ₹1,818.37m, up from ₹12,969.88m and ₹1,306.06m in Q2 2026. Net margin moved from 10.1% to 11.6%. That pattern supported the view that higher capacity and peptides could be associated with both sales and profitability. However, it did not address longer project paybacks or balance sheet pressure, so the overall picture remained mixed.

The key issue was whether higher capital spend would translate into healthier earnings. For any other stock, investors can track whether net income and margin move in the same direction as expansion projects, and then test if that relationship is consistent across more than one reporting period.

What Granules India's Run Now Asks You To Believe

Granules India now trades at ₹800, with this Narrative’s Fair Value sitting below that level. The tension is not about whether the business can grow. It is about how much of that potential is already implied in the quotation on screen.

The selected Narrative argues that the current price assumes cost inflation, remediation spend and peptide CDMO swings all stay contained. Any buyer today effectively has to judge that margins and cash generation can hold up even if those pressures remain stubborn.

"The numbers imply that, if these pressures on margins and cash generation persist against current expectations, Granules India's share price embeds a richer outcome than recent input cost trends, remediation spend and peptide CDMO volatility alone would justify."

The price and this Narrative do not agree. → Uncover what this Narrative says Granules India is actually worth

Go Straight To The Source

By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.

• Company 1 - 20% below our estimate - builds injectable antibiotic bone grafts surgeons reuse as infection risks and reimbursements evolve.
• Company 2 - 40% below our estimate - sells high end AI chips whose demand depends on data centre power infrastructure.
• Company 3 - 19% below our estimate - ships custom security hardware tied to a single operating system to deepen customer lock in.

That is three of the list. See every one of the 193 solid balance sheet companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com